Viral vector platforms within the gene therapy landscape
Throughout its 40-year history, the field of gene therapy has been marked by many
transitions. It has seen great strides in combating human disease, has given hope to patients …
transitions. It has seen great strides in combating human disease, has given hope to patients …
COVID-19: coronavirus vaccine development updates
J Zhao, S Zhao, J Ou, J Zhang, W Lan, W Guan… - Frontiers in …, 2020 - frontiersin.org
Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since …
Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since …
Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine
CS Lee, ES Bishop, R Zhang, X Yu, EM Farina, S Yan… - Genes & diseases, 2017 - Elsevier
With rapid advances in understanding molecular pathogenesis of human diseases in the era
of genome sciences and systems biology, it is anticipated that increasing numbers of …
of genome sciences and systems biology, it is anticipated that increasing numbers of …
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
S Wang, B Liang, W Wang, L Li, N Feng… - Signal transduction and …, 2023 - nature.com
Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …
challenges to public health security and the global economy. The development and …
Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial
Importance Develo** effective vaccines against Ebola virus is a global priority. Objective
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26 …
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26 …
A review of 65 years of human adenovirus seroprevalence
FJD Mennechet, O Paris, AR Ouoba… - Expert review of …, 2019 - Taylor & Francis
ABSTRACT Introduction: Human adenovirus (HAdV)-derived vectors have been used in
numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV …
numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV …
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept …
GE Gray, M Allen, Z Moodie, G Churchyard… - The Lancet infectious …, 2011 - thelancet.com
Summary Background The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to
elicit T-cell-mediated immune responses capable of providing complete or partial protection …
elicit T-cell-mediated immune responses capable of providing complete or partial protection …
Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism
P Rzymski, B Perek, R Flisiak - Vaccines, 2021 - mdpi.com
The rollout of COVID-19 vaccines brings hope for successful pandemic mitigation and
getting the transmission of SARS-CoV-2 under control. The vaccines authorized in Europe …
getting the transmission of SARS-CoV-2 under control. The vaccines authorized in Europe …
[HTML][HTML] Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment
J Custers, D Kim, M Leyssen, M Gurwith, F Tomaka… - Vaccine, 2021 - Elsevier
Replication-incompetent adenoviral vectors have been under investigation as a platform to
carry a variety of transgenes, and express them as a basis for vaccine development. A …
carry a variety of transgenes, and express them as a basis for vaccine development. A …
Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
H Fausther-Bovendo, GP Kobinger - Human vaccines & …, 2014 - Taylor & Francis
Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the
human population is widespread, thus hampering its clinical use. Various components of the …
human population is widespread, thus hampering its clinical use. Various components of the …